Cabaletta Bio, Inc. (CABA:NASDAQ) closed at $1.35 on October 26, 2026, down 8.16% on the day. The stock trades 68.1% below its 52-week high of $4.23 and 2.3% above its 52-week low of $1.32. Over the past year, it lost 51.6%. Cabaletta Bio, Inc. is part of the Health Care sector.
In 252 trading sessions since October 24, 2025, CABA closed higher on 103 days (41%). Its best day was October 31, 2025 (+46.15%) and its worst was November 3, 2025 (-16.62%). The stock moved 10% or more in a single session 14 times. It opened at least 5% above the previous day's high 2 times.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its technology uses chimeric autoantibody receptor T cells that are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies while sparing normal B cells. The firm offers preclinical development for the treatment of muscle-specific kinase myasthenia gravis, mucocutaneous PV, and Hemophilia A with factor VIII, or FVIII, alloantibodies. Its products comprise of DSG3/1-CAART, MuSK-CAART, and FVIII-CAART. The firm's initial focus is on Pemphigus Vulgaris, which is an autoimmune blistering skin disease.
Find more stocks like CABA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.